RVNC•benzinga•
Needham Gives Revance Therapeutics Buy Rating With Note Titled: FDA Approves Daxxify With Anticipated Product Label Differentiation; Raises Price Target From $25 To $35
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 8, 2022 by benzinga